

PRESS RELEASE April 24, 2008

Resolutions from Biovitrums AGM

The Biovitrum Annual General Meeting (AGM) convened earlier today in Stockholm and voted in favor of all resolutions proposed at the meeting, including:

The AGM approved the proposal to carry forward the retained profits of SEK 592,820,640.

The AGM discharged the members of the Board and the President from liability for the fiscal year 2007.

The ordinary Board Members Håkan Åström, Anders Hultin, Wenche Rolfsen, Michael Steinmetz, Toni Weitzberg, Hans Wigzell and Mats-Olof Ljungkvist were re-elected and Håkan Åström was elected Chairman of the Board.

The AGM approved the 2008 compensation to the Board totaling SEK 2,650,000, of which SEK 950,000 is paid to the Chairman, and SEK 250,000 is paid to each of the other Board Members. The compensation for work in the committees of the Board was approved at SEK 50,000 to the chairman of the Audit Committee and SEK 25,000 to the other members of the Audit Committee and that no compensation will be received by the members of the Remuneration Committee. The AGM also approved compensation for work in the Scientific Committee at SEK 50,000 to the Chairman and SEK 25,000 to each of the other members in the committee.

The AGM approved the Board's proposals regarding the guidelines for remuneration etcetera for the Management, as well as the scope of and the main principles for Biovitrum's new performance based, long-term share program for 2008 comprising a resolution regarding amendment of the articles of association, a resolution regarding a directed issue of series C shares and a resolution regarding authorization for the Board to repurchase issued series C shares.

The AGM decided to approve the instructions and charter for the Nomination Committee.

Furthermore, the AGM decided to authorize the Board to resolve to issue new shares.

At the statutory meeting of the Board held in conjunction with the AGM, Mats-Olof Ljungkvist (Chairman), Anders Hultin and Håkan Åström were elected to the Audit Committee, and Toni Weitzberg (Chairman), Håkan Åström and Michael Steinmetz to the Remuneration Committee. Michael Steinmetz (Chairman), Hans Wigzell and Wenche Rolfsen were elected to the Scientific Committee.

For full details on each proposal adopted by the AGM please refer to www.biovitrum.com where documentation related to the AGM is published.

President and CEO Martin Nicklasson address to the meeting will be available at www.biovitrum.com.

For more information, contact:

Biovitrum AB (publ)

Martin Nicklasson, CEO

Phone: +46 8 697 20 00

martin.nicklasson@biovitrum.com

Erik Kinnman, Vice President, Investor Relations & Public Affairs

Phone: +46 73 422 15 40

erik.kinnman@biovitrum.com

Facts to the editor

About Biovitrum

Biovitrum is a pharmaceutical company with operations in Sweden and in the UK. Biovitrum has currently a research portfolio with several projects in clinical and preclinical phases for a number of well defined specialist indications as well as for common diseases within obesity, diabetes, inflammation and eye diseases. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has revenues of approximately SEK 1.2 billion and around 500 employees. Biovitrum's share is listed on the OMX Nordic Exchange in Stockholm since September 15, 2006. For more information see www.biovitrum.com.

Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Market Act.